Pall invests in virus inactivation technology:
This article was originally published in Clinica
Pall Corporation has released $3 million in a milestone payment to VI Technologies as it enters Phase I clinical trials on its proprietary INACTINE red blood cell inactivation technology. VI Technologies, of Melville, New York, estimates that the potential market for virally-inactivated red blood cells could exceed $2 billion annually.
You may also be interested in...
The US Food and Drug Administration posted two device-related closeout letters in November.
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.
As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.